Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO5093151 Topical in Glaucoma or Ocular Hypertension
NCT02622334Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of RO5093151 in primary open-angle glaucoma (POAG) and ocular hypertension (6 arms), sponsored by Roche. Primary endpoints: Incidence of adverse events up to 12 weeks and Change in mean IOP after 7 days treatment vs baseline. Started Dec 2015; status: completed.
02
Drugs
RO5093151
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT02622334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02622334.